Raymond James Financial Services Advisors, Inc. Crispr Therapeutics Ag Transaction History
Raymond James Financial Services Advisors, Inc.
- $73.5 Billion
- Q3 2024
A detailed history of Raymond James Financial Services Advisors, Inc. transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Raymond James Financial Services Advisors, Inc. holds 61,783 shares of CRSP stock, worth $2.65 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
61,783
Previous 57,431
7.58%
Holding current value
$2.65 Million
Previous $3.1 Million
6.39%
% of portfolio
0.0%
Previous 0.0%
Shares
25 transactions
Others Institutions Holding CRSP
# of Institutions
480Shares Held
64.2MCall Options Held
2.15MPut Options Held
1.92M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl10.2MShares$437 Million3.73% of portfolio
-
Capital International Investors Los Angeles, CA6.07MShares$261 Million0.04% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.8MShares$163 Million0.09% of portfolio
-
Black Rock Inc. New York, NY2.78MShares$119 Million0.0% of portfolio
-
Nikko Asset Management Americas, Inc.2.54MShares$109 Million1.16% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $3.35B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....